4//SEC Filing
Aziz Kabeer 4
Accession 0000950170-24-005515
CIK 0001880438other
Filed
Jan 17, 7:00 PM ET
Accepted
Jan 18, 6:19 PM ET
Size
7.3 KB
Accession
0000950170-24-005515
Insider Transaction Report
Form 4
Aziz Kabeer
Director
Transactions
- Sale
Common Stock
2024-01-16$19.65/sh−84,093$1,652,427→ 1,995,958 total(indirect: By Adjuvant Global Health Technology Fund, L.P.) - Sale
Common Stock
2024-01-16$19.65/sh−15,907$312,573→ 377,542 total(indirect: By Adjuvant Global Health Technology Fund DE, L.P.)
Footnotes (2)
- [F1]Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.
- [F2]Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.
Documents
Issuer
AN2 Therapeutics, Inc.
CIK 0001880438
Entity typeother
Related Parties
1- filerCIK 0001914847
Filing Metadata
- Form type
- 4
- Filed
- Jan 17, 7:00 PM ET
- Accepted
- Jan 18, 6:19 PM ET
- Size
- 7.3 KB